Nas­daq delists In­sys af­ter bank­rupt­cy fil­ing; Chi­na's Zai Lab li­cens­es sol­id tu­mor drug from De­ci­phera

→ On the heels of a bank­rupt­cy fil­ing, In­sys an­nounced that it’s get­ting delist­ed from the Nas­daq. Trad­ing of the stock $IN­SY — rel­e­gat­ed to the over-the-mar­ket these days — will come to a halt on June 19, 2019. The opi­oid mak­er, which agreed to pay $225 mil­lion to set­tle the US gov­ern­ment’s in­ves­ti­ga­tions in­to the mar­ket­ing prac­tices around its fen­tanyl spray Sub­sys, does not plan on ap­peal­ing the de­ter­mi­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER